Function of topoisomerase II and the consequences of inhibition.
Davies
S M
SM
Division of Clinical Research and Epidemiology, University of Minnesota, Minneapolis, USA.
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D001695:Biology; D002648:Child; D004249:DNA Damage; D004250:DNA Topoisomerases, Type II / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D007938:Leukemia / Q000139:chemically induced; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D059005:Topoisomerase II Inhibitors
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors; D004250:DNA Topoisomerases, Type II